Vamil Divan Analyst Performance

Senior Biopharmaceuticals Research Analyst at Guggenheim

Vamil Divan is a stock analyst at Guggenheim in the medical sector, covering 43 publicly traded companies. Over the past year, Vamil Divan has issued 33 stock ratings, including buy and hold recommendations. While full access to Vamil Divan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Vamil Divan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 279 Last 11 Years
Buy Recommendations: 58.52% 158 Buy Ratings
Companies Covered: 43 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.4%	1 ratings
Buy	58.1%	157 ratings
Hold	35.9%	97 ratings
Sell	5.6%	15 ratings

Out of 270 total stock ratings issued by Vamil Divan at Guggenheim, the majority (58.1%) have been Buy recommendations, followed by 35.9% Hold, 5.6% Sell, and 0.4% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
IRMD
Nov 2017
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
BHVN
Oct 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	79.1% of companies on NASDAQ	34 companies
NYSE	20.9% of companies on NYSE	9 companies

Vamil Divan, an analyst at Guggenheim, currently covers 43 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 43 companies	100.0%

Vamil Divan of Guggenheim specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 15 companies	34.9%
PHARMACEUTICAL PREPARATIONS 11 companies	25.6%
MED - DRUGS 6 companies	14.0%
LARGE CAP PHARMA 5 companies	11.6%
MED - GENERIC DRG 2 companies	4.7%
MED PRODUCTS 2 companies	4.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	2.3%
MED INSTRUMENTS 1 company	2.3%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
JNJ Johnson & Johnson	9/23/2025	Upgrade	$174.22	$206.00	Buy
SVRA Savara	9/9/2025	Boost Price Target	$3.85	$11.00	Buy
INSM Insmed	9/8/2025	Boost Price Target	$145.83	$172.00	Buy
ASMB Assembly Biosciences	9/8/2025	Boost Price Target	$23.80	$39.00	Buy
VALN Valneva	9/8/2025	Lower Price Target	$8.34	$13.00	Buy
ANIP ANI Pharmaceuticals	9/8/2025	Boost Price Target	$95.91	$114.00	Buy
ABBV AbbVie	8/1/2025	Boost Price Target	$193.55	$227.00	Buy
JNJ Johnson & Johnson	7/17/2025	Reiterated Rating	$163.41	$167.00	Neutral
PROK ProKidney	7/14/2025	Reiterated Rating	$3.91	$7.00	Buy
JBIO Jade Biosciences	6/16/2025	Upgrade	$6.76	$14.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
SVRA Savara	5/28/2025	Reiterated Rating	$2.04	$8.00	Buy
AMGN Amgen	5/20/2025	Initiated Coverage	$276.16	$288.00	Neutral
ANIP ANI Pharmaceuticals	5/12/2025	Reiterated Rating	$63.63	$86.00	Buy
VALN Valneva	5/8/2025	Lower Price Target	$6.28	$14.00	Buy
ABBV AbbVie	4/29/2025	Boost Price Target	$192.43	$216.00	Buy
UNCY Unicycive Therapeutics	4/21/2025	Initiated Coverage	$6.00	$60.00	Buy
ABBV AbbVie	4/17/2025	Reiterated Rating	$173.24	$214.00	Buy
MRK Merck & Co., Inc.	4/17/2025	Reiterated Rating	$78.09	$115.00	Buy
TVTX Travere Therapeutics	4/14/2025	Reiterated Rating	$14.76	$47.00	Buy
ANIP ANI Pharmaceuticals	4/11/2025	Reiterated Rating	$65.86	$86.00	Buy
JNJ Johnson & Johnson	4/2/2025	Reiterated Rating	$155.02		Neutral
ASMB Assembly Biosciences	3/25/2025	Initiated Coverage	$11.12	$31.00	Buy
PFE Pfizer	3/18/2025	Reiterated Rating	$26.27		Buy
PFE Pfizer	3/12/2025	Reiterated Rating	$25.67		Buy
JNJ Johnson & Johnson	3/10/2025	Reiterated Rating	$168.77		Neutral
ANIP ANI Pharmaceuticals	3/5/2025	Boost Price Target	$59.23	$86.00	Buy
VERA Vera Therapeutics	2/27/2025	Boost Price Target	$29.14	$61.00	Buy
INSM Insmed	2/25/2025	Reiterated Rating	$78.46	$101.00	Buy
MRK Merck & Co., Inc.	2/12/2025	Lower Price Target	$86.53	$115.00	Buy
PFE Pfizer	2/10/2025	Reiterated Rating	$25.76	$33.00	Buy
INSM Insmed	2/7/2025	Boost Price Target	$79.71	$101.00	Buy
JNJ Johnson & Johnson	2/3/2025	Boost Price Target	$152.09	$166.00	Neutral
ABBV AbbVie	2/3/2025	Boost Price Target	$183.90	$214.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.